Zimmer Biomet Holdings, Inc. (ZBH): Among the Best Medical Device Stocks to Buy Now
On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president's newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back.
The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation:
'MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.'
Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined:
'The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.'
READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds.
President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump's second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices.
Casey Hite, CEO of Aeroflow Health, a firm that provides insurance-covered medical devices, said the following:
'With the level of tariffs that we're looking at in China, businesses are going to be completely upside down on these products … they can't pass those costs on to the consumer. I think what we would like to see, more than anything, is a runway or some predictability. Let's do this over the next 12 months, next two years, so that US organizations can prepare.'
We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best medical device stocks and then chose the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points ().
A team of medical specialists discussing orthopaedic reconstructive surgery plans.
Number of Hedge Fund Holders: 53
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) designs, manufactures, and markets orthopedic reconstructive products. It also offers biologics, extremities, sports medicine, dental implants, trauma products, and related surgical products.
The company leads the orthopedic sector with a 36% share in knee implants and a 23% share in hip implants. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) also holds a competitive market advantage due to its regulatory expertise, as the development of medical implants requires a lengthy FDA approval process, creating a natural barrier to entry and limiting competition.
On April 25, BTIG analyst Ryan Zimmerman maintained a Buy rating on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) and set a price target of $123.00. The analyst said that the company's recent strategic product introductions in the hip replacement sector position it well to regain market share.
The company has launched innovative products such as the Z1 Triple Taper Stem, HAMMR, and OrthoGrid, which have received generally optimistic feedback from orthopedic surgeons. The products can improve Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) competitive position, supporting the Buy rating.
Overall, ZBH ranks 11th on our list of the best medical device stocks to buy now. While we acknowledge the potential for ZBH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ZBH but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
NYSE Content Advisory: Pre-market update + NIQ to debut, NYSE joins AI Summit
NEW YORK, July 23, 2025 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. The NYSE is participating at the All In and Hill and Valley's "Winning the AI Race" Summit, capturing insights from key voices shaping the future of business, technology, and innovation. Ashley Mastronardi delivers the pre-market update on July 23rd Stocks are fractionally higher Wednesday morning after President Trump announced a "massive deal" with Japan. This move includes a reciprocal tariff of 15% on exports to the U.S. and Japan investing $550 Billion to the U.S. Investors are also paying attention to a slew of earnings throughout the day including NYSE-listed telecommunications giant AT&T. Tesla and Alphabet headline earnings after market close. Consumer intelligence company NielsenIQ celebrates its IPO at the NYSE this morning. The company, which raised over $1 billion, will ring the opening bell and begin trading under the ticker symbol NIQ. The NYSE is participating in the All In and Hill & Valley "Winning the AI Race" Summit in Washington D.C., engaging with influential leaders and innovators to gather strategic insights on the evolving intersection of AI, business, and technology. Opening BellNielsenIQ (NYSE: NIQ) celebrates its initial public offering Closing BellGotham FC celebrates becoming the first American women's pro soccer club to win a continental competition Click here to download the NYSE TV App View original content to download multimedia: SOURCE New York Stock Exchange View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Should You Consider Selling Your Stake in JBG SMITH Properties (JBGS)?
Aristotle Capital Boston, LLC, an investment advisor, released its 'Small Cap Equity Strategy' second quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter started with a risk-off environment from the previous quarter, but later regained momentum driven by broad-based elements. In the second quarter, the strategy delivered a return of 3.25% net of fees (3.41% gross of fees) underperforming the 8.50% total return of the Russell 2000 Index. For more information on the fund's best picks in 2025, please check its top five holdings. In its second quarter 2025 investor letter, Aristotle Capital Small Cap Equity Strategy highlighted stocks such as JBG SMITH Properties (NYSE:JBGS). JBG SMITH Properties (NYSE:JBGS) is a real estate investment trust that owns, operates, and develops mixed-use properties concentrated in amenity-rich, Metro-served submarkets. The one-month return of JBG SMITH Properties (NYSE:JBGS) was 12.30%, and its shares gained 14.36% of their value over the last 52 weeks. On July 22, 2025, JBG SMITH Properties (NYSE:JBGS) stock closed at $18.71 per share, with a market capitalization of $1.412 billion. Aristotle Capital Small Cap Equity Strategy stated the following regarding JBG SMITH Properties (NYSE:JBGS) in its second quarter 2025 investor letter: "JBG SMITH Properties (NYSE:JBGS), a Washington, DC-focused real estate investment trust that develops, owns and operates a portfolio of mixed-use properties (multifamily, commercial, development and land assets). Concerns related to the company's capital allocation plans along with deteriorating fundamentals in their core operating market prompted our decision to exit the position." A view of a bustling city skyline featuring the public company's high-growth office buildings. JBG SMITH Properties (NYSE:JBGS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held JBG SMITH Properties (NYSE:JBGS) at the end of the first quarter, which was 14 in the previous quarter. While we acknowledge the potential of JBG SMITH Properties (NYSE:JBGS) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Myriad Uranium Corp. to Present at the Metals & Mining Virtual Investor Conference July 24, 2025
The Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Myriad Uranium Corp. ('Myriad' or the 'Company') (OTCQB: MYRUF) (CSE: M) (FSE: C3Q), a uranium exploration company with an earnable 75% interest in the Copper Mountain Uranium Project in Wyoming, USA, and a 100% interest in the Red Basin Project in New Mexico, today announced that Thomas Lamb, CEO, will present live at the Metals & Mining Virtual Investor Conference hosted by on July 24, 2025. DATE: July 24, 2025 TIME: 2:30 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: July 25 and July 28, 2025. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Upcoming Project Catalyst An important upcoming project catalyst is the assay of roughly 1,500 additional samples from late 2024 drilling. The results, if broadly positive, could confirm extensive entirely new mineralization at Copper Mountain that is largely unaccounted for by gamma and DFN probe measurements due to the effects of 'secular disequilibrium' (a state where the radioactive decay products of uranium are not in equilibrium with their parent uranium isotopes). Positive results could significantly enhance the grades and interval thicknesses, which in turn could enhance the resources and economics of the project. Union Pacific was already on track to develop the project into a large-scale uranium mine in the late 1970s. Important details are discussed in the recent news release viewable here. About Myriad Uranium Corp. Myriad is a uranium exploration company advancing the Copper Mountain Uranium Project in Wyoming, USA, where it holds an earnable 75% interest. Copper Mountain hosts multiple known uranium deposits and past-producing mines, including the Arrowhead Mine, which produced 500,000 lbs of U₃O₈ during the 1950s and 60s (Cramer et al., 1977a, and subsequent references). The project was extensively explored and developed by Union Pacific in the late 1970s, resulting in the identification of seven uranium deposits and fifteen additional prospects. A detailed mine plan was prepared to supply uranium for proposed reactors by California Edison, but operations were halted in 1980 due to collapsing uranium prices before mining could commence. To date, approximately 2,000 boreholes have been drilled at Copper Mountain. Union Pacific is estimated to have invested US$78 million (2024 dollars) into exploration and development, including significant historical resource estimates. These historical figures, if validated and expanded, could position Copper Mountain as one of the largest uranium projects in the United States. The property also offers substantial exploration upside. In addition, Myriad recently secured, subject to a planned geophysical survey in 2025, a 100% interest in the Red Basin Uranium Project in New Mexico. Red Basin contains shallow historical uranium resources and offers strong potential for resource expansion (Chamberlin, 1981). The announcement regarding the Red Basin acquisition can be viewed here and a subsequent announcement regarding an expansion of the Company's acreage to encompass ~800 of 1,050 historical boreholes in the basin can be viewed here. Our Crux Investor overview page including recent interviews can be viewed here. The Company's presentation can be viewed here. News releases regarding historical drilling can be viewed here and here. A news release summarising recent chemical assays of 2024 Copper Mountain drilling can be viewed here. Myriad also has a 50% interest in the Millen Mountain Property in Nova Scotia, Canada, with the other 50% held by Probe Gold Inc. For further information, please refer to Myriad's disclosure record on SEDAR+ ( contact Myriad by telephone at +1.604.418.2877, or refer to Myriad's website at About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Myriad Uranium LambCEO+1 (604) 418-2877tlamb@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@